Eledon Pharmaceuticals Q3 2026 Results: Net Loss of $3.93M, Loss Narrows
For the nine months ended September 30, 2026, Eledon Pharmaceuticals reported a net loss of $74.6 million, a significant increase from the $35.2 million loss in the prior year period, primarily driven by a $11.6 million unfavorable change in the fair value of warrant liabilities. Total assets decreased to $106.6 million from $169.0 million at year-end 2025, reflecting a reduction in cash and short-term investments used to fund ongoing research and development operations.
- Key figure
- Net loss $3.93M